NI201900092A - Combinación farmacéutica que comprende ponesimod - Google Patents

Combinación farmacéutica que comprende ponesimod

Info

Publication number
NI201900092A
NI201900092A NI201900092A NI201900092A NI201900092A NI 201900092 A NI201900092 A NI 201900092A NI 201900092 A NI201900092 A NI 201900092A NI 201900092 A NI201900092 A NI 201900092A NI 201900092 A NI201900092 A NI 201900092A
Authority
NI
Nicaragua
Prior art keywords
ponesimod
pharmaceutical combination
combination including
active ingredient
teriflunomide
Prior art date
Application number
NI201900092A
Other languages
English (en)
Spanish (es)
Inventor
Clozel Martine
Ágainé Csongor Éva
Pouzol Laetitia
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NI201900092A publication Critical patent/NI201900092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
NI201900092A 2017-03-14 2019-09-11 Combinación farmacéutica que comprende ponesimod NI201900092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Publications (1)

Publication Number Publication Date
NI201900092A true NI201900092A (es) 2020-03-11

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900092A NI201900092A (es) 2017-03-14 2019-09-11 Combinación farmacéutica que comprende ponesimod

Country Status (24)

Country Link
US (2) US11723896B2 (enExample)
EP (1) EP3595657A1 (enExample)
JP (3) JP7281406B2 (enExample)
KR (1) KR102574562B1 (enExample)
CN (1) CN110381942B (enExample)
AU (2) AU2018233109B2 (enExample)
BR (1) BR112019018894A2 (enExample)
CA (1) CA3056301C (enExample)
CL (1) CL2019002525A1 (enExample)
CO (1) CO2019008510A2 (enExample)
CR (1) CR20190464A (enExample)
DO (1) DOP2019000257A (enExample)
EA (1) EA201992117A1 (enExample)
EC (1) ECSP19073317A (enExample)
IL (1) IL269239B2 (enExample)
JO (1) JOP20190207A1 (enExample)
MA (1) MA49822A (enExample)
MX (1) MX390941B (enExample)
NI (1) NI201900092A (enExample)
PE (1) PE20191489A1 (enExample)
PH (1) PH12019502110A1 (enExample)
SG (1) SG11201907308UA (enExample)
UA (1) UA125756C2 (enExample)
WO (1) WO2018167030A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6723855B2 (en) * 2000-02-15 2004-04-20 Teva Pharmaceutical Industries Ltd. Method for synthesizing leflunomide
AR033459A1 (es) 2001-04-05 2003-12-17 Aventis Pharma Inc Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
PL1689726T3 (pl) 2003-11-21 2011-05-31 Actelion Pharmaceuticals Ltd Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne
CA2584655A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
EP2489662B1 (en) 2006-11-23 2014-08-06 Actelion Pharmaceuticals Ltd. Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives
BRPI0909625B1 (pt) 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
SI2477611T1 (sl) 2009-09-18 2017-07-31 Sanofi Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
EP2600861A1 (en) 2010-08-02 2013-06-12 Sanofi-Aventis U.S. LLC Use of teriflunomide for treating multiple sclerosis
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HUE050733T2 (hu) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
AU2015359346B2 (en) 2014-12-11 2020-05-07 Laboratoires Juvise Pharmaceuticals Dosing regimen for a selective S1P1 receptor agonist
CN107920991A (zh) 2015-06-18 2018-04-17 马丁尼斯生物制药纳米技术公司 治疗炎性疾病或病状的组合物和方法
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Also Published As

Publication number Publication date
MX390941B (es) 2025-03-21
WO2018167030A1 (en) 2018-09-20
PH12019502110A1 (en) 2020-03-16
EP3595657A1 (en) 2020-01-22
JP2024096962A (ja) 2024-07-17
US20200069655A1 (en) 2020-03-05
PE20191489A1 (es) 2019-10-21
MA49822A (fr) 2020-06-17
KR20190122716A (ko) 2019-10-30
DOP2019000257A (es) 2020-09-15
MX2019010874A (es) 2019-12-11
AU2018233109A1 (en) 2019-08-22
ECSP19073317A (es) 2019-11-30
IL269239A (en) 2019-11-28
EA201992117A1 (ru) 2020-02-17
IL269239B1 (en) 2023-03-01
AU2023274118B2 (en) 2024-12-12
AU2023274118A1 (en) 2023-12-21
CL2019002525A1 (es) 2020-02-07
JOP20190207A1 (ar) 2019-09-10
CO2019008510A2 (es) 2019-10-21
IL269239B2 (en) 2023-07-01
JP2023030091A (ja) 2023-03-07
CA3056301A1 (en) 2018-09-20
AU2018233109B2 (en) 2023-09-28
BR112019018894A2 (pt) 2020-04-14
CN110381942A (zh) 2019-10-25
CN110381942B (zh) 2022-12-27
KR102574562B1 (ko) 2023-09-04
JP7281406B2 (ja) 2023-05-25
CR20190464A (es) 2019-11-26
SG11201907308UA (en) 2019-09-27
CA3056301C (en) 2024-10-01
US20240139161A1 (en) 2024-05-02
UA125756C2 (uk) 2022-06-01
JP2020510045A (ja) 2020-04-02
US11723896B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
ECSP19073317A (es) Combinación farmacéutica que comprende ponesimod
MX2020006150A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
CR20170099A (es) Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
MX2017015579A (es) Formas de dosificacion solidas de palbociclib.
EP3725321A4 (en) COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
IL266279B1 (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
CY1122310T1 (el) Εκχυλισμα γαρδενιας για τον χρωματισμο του δερματος
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CL2018000282A1 (es) Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol
MX388400B (es) Una composición de dos componentes, que comprende ácido acetilsalicílico.
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
ECSP19006687A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl-1, usos y composiciones farmacéuticas de éstos
CY1122979T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EA201792093A1 (ru) 2-тиопиримидиноны
UY36273A (es) Composicion para el tratamiento de neuropatías y del dolor neuropático
EA201990162A1 (ru) Фармацевтические композиции
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
CL2020001705A1 (es) Composición acuosa que comprende ácido 2-(dimetil-1h-pirazol-1-il) succínico y amoníaco.
CL2016003273A1 (es) Composiciones antimicrobianas con agentes efervescentes